Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023
Arthritis Care & Research · 2026
DOI: 10.1002/acr.70042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Danielle Dawson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can lead to death. To examine SLE as an underlying and contributing cause of death, the Centers for Disease Control and Prevention (CDC) analyzed 2018 to 2023 mortality data for persons aged ≥15 years overall and by age, sex, race and ethnicity, and region.
Methods
Death certificate data for persons aged ≥15 years with any mention of SLE ( International Classification of Diseases, Tenth Revision [ICD‐10] code M32) were analyzed using the CDC Wide‐ranging Online Data for Epidemiologic Research (WONDER) system. We calculated age‐adjusted death rates and assessed patterns by sex, age, race and ethnicity, and region. Underlying and contributing causes of death were evaluated using ranked cause‐of‐death lists and ICD‐10 subchapters.
Results
During 2018 to 2023, 14,936 deaths had any mention of SLE listed on the death certificates. Of these deaths, 6,414 (42.9%) listed SLE as the underlying cause. The age‐adjusted SLE mortality rate per million population was greater among females (5.97) than males (1.16), non‐Hispanic African American persons (10.70) than persons of other non‐Hispanic racial groups (range 2.46–5.62), Hispanic persons (3.98) than non‐Hispanic persons (3.59), and people in the South (4.37) than people in other regions. When SLE was listed as a contributing cause of death, the leading underlying causes were heart disease (0.93), cancer (0.56), and COVID‐19 (0.51). The overall age‐adjusted SLE mortality rates were significantly higher in 2020 and 2021 than in all other study years, indicating the likely impact of the COVID‐19 pandemic on SLE mortality.
Conclusion
Overall management of SLE, comorbidities, and infections in patients with SLE, as well as interventions targeting groups (eg, African American persons) disproportionately impacted by SLE, may reduce overall SLE mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centers for Disease Control and Prevention, Atlanta, Georgia.
- Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.
Zitieren
APA
Dawson, D., Greenlund, K. J., & Barbour, K. E. (2026). Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023. Arthritis Care & Research. https://doi.org/10.1002/acr.70042
Vancouver
Dawson D, Greenlund KJ, Barbour KE. Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023. Arthritis Care & Research. 2026. doi:10.1002/acr.70042
BibTeX
@article{Dawson2026,
author = {Dawson, Danielle and Greenlund, Kurt J and Barbour, Kamil E},
title = {Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.70042}
}
EUVIMED